European experience of docetaxel and cisplatin in advanced gastric cancer

The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response rate of 56%) with a manageable safety profile. Up to...

Full description

Saved in:
Bibliographic Details
Published in:Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2002, Vol.5 Suppl 1 (S1), p.27-29
Main Author: Roth, Arnaud D
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - administration & dosage
Disease Progression
Disease-Free Survival
Female
Fluorouracil - administration & dosage
Gastric cancer
Humans
Male
Middle Aged
Oncology
Paclitaxel - administration & dosage
Paclitaxel - analogs & derivatives
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Taxoids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2825-84fa14c5a64550e47c346ad233bd4d40e4497f9b4b5aaee334b0e8c81a102bc03
cites cdi_FETCH-LOGICAL-c2825-84fa14c5a64550e47c346ad233bd4d40e4497f9b4b5aaee334b0e8c81a102bc03
container_end_page 29
container_issue S1
container_start_page 27
container_title Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
container_volume 5 Suppl 1
creator Roth, Arnaud D
description The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response rate of 56%) with a manageable safety profile. Up to 300 mg/m2 5-fluorouracil (5-FU) given by continuous infusion for 2 of 3 weeks can be added to this regimen without an increase in appreciable toxicity. The efficacy of docetaxel-based regimens remains to be established by a randomized phase III study. However, the results of such trials are eagerly awaited, as are data from studies of docetaxel-based combinations in the adjuvant and neoadjuvant settings.
doi_str_mv 10.1007/s10120-002-0204-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_220178037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>944522761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2825-84fa14c5a64550e47c346ad233bd4d40e4497f9b4b5aaee334b0e8c81a102bc03</originalsourceid><addsrcrecordid>eNpFkFtLw0AQhRdRbK3-AF9k8T06e8vlUUrVQsEXfV4muxNJaZO4m0j996Y0IgzMhXPOwMfYrYAHAZA9RgFCQgIgE5CgE3PG5kKrNFEKzPnfLAsxY1cxbgGEKUR6yWZCZpnMcz1n69UQ2o6w4XToKNTUOOJtxX3rqMcD7Tg2nrs6djvs64aPhf4bR5Xnnxj7UDvujmu4ZhcV7iLdTH3BPp5X78vXZPP2sl4-bRInc2mSXFcotDOYamOAdOaUTtFLpUqvvR4vusiqotSlQSRSSpdAucsFCpClA7Vg96fcLrRfA8XebtshNONLKyWILAeVjSJxErnQxhiosl2o9xh-rAB7ZGdP7OzIzh7ZWTN67qbgodyT_3dMsNQvsf5o_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220178037</pqid></control><display><type>article</type><title>European experience of docetaxel and cisplatin in advanced gastric cancer</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>Roth, Arnaud D</creator><creatorcontrib>Roth, Arnaud D</creatorcontrib><description>The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response rate of 56%) with a manageable safety profile. Up to 300 mg/m2 5-fluorouracil (5-FU) given by continuous infusion for 2 of 3 weeks can be added to this regimen without an increase in appreciable toxicity. The efficacy of docetaxel-based regimens remains to be established by a randomized phase III study. However, the results of such trials are eagerly awaited, as are data from studies of docetaxel-based combinations in the adjuvant and neoadjuvant settings.</description><identifier>ISSN: 1436-3291</identifier><identifier>EISSN: 1436-3305</identifier><identifier>DOI: 10.1007/s10120-002-0204-5</identifier><identifier>PMID: 12772884</identifier><language>eng</language><publisher>Japan: Springer Nature B.V</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cisplatin - administration &amp; dosage ; Disease Progression ; Disease-Free Survival ; Female ; Fluorouracil - administration &amp; dosage ; Gastric cancer ; Humans ; Male ; Middle Aged ; Oncology ; Paclitaxel - administration &amp; dosage ; Paclitaxel - analogs &amp; derivatives ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - pathology ; Taxoids</subject><ispartof>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2002, Vol.5 Suppl 1 (S1), p.27-29</ispartof><rights>International and Japanese Gastric Cancer Associations 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2825-84fa14c5a64550e47c346ad233bd4d40e4497f9b4b5aaee334b0e8c81a102bc03</citedby><cites>FETCH-LOGICAL-c2825-84fa14c5a64550e47c346ad233bd4d40e4497f9b4b5aaee334b0e8c81a102bc03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,4043,27956,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12772884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roth, Arnaud D</creatorcontrib><title>European experience of docetaxel and cisplatin in advanced gastric cancer</title><title>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</title><addtitle>Gastric Cancer</addtitle><description>The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response rate of 56%) with a manageable safety profile. Up to 300 mg/m2 5-fluorouracil (5-FU) given by continuous infusion for 2 of 3 weeks can be added to this regimen without an increase in appreciable toxicity. The efficacy of docetaxel-based regimens remains to be established by a randomized phase III study. However, the results of such trials are eagerly awaited, as are data from studies of docetaxel-based combinations in the adjuvant and neoadjuvant settings.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cisplatin - administration &amp; dosage</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fluorouracil - administration &amp; dosage</subject><subject>Gastric cancer</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Paclitaxel - administration &amp; dosage</subject><subject>Paclitaxel - analogs &amp; derivatives</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - pathology</subject><subject>Taxoids</subject><issn>1436-3291</issn><issn>1436-3305</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpFkFtLw0AQhRdRbK3-AF9k8T06e8vlUUrVQsEXfV4muxNJaZO4m0j996Y0IgzMhXPOwMfYrYAHAZA9RgFCQgIgE5CgE3PG5kKrNFEKzPnfLAsxY1cxbgGEKUR6yWZCZpnMcz1n69UQ2o6w4XToKNTUOOJtxX3rqMcD7Tg2nrs6djvs64aPhf4bR5Xnnxj7UDvujmu4ZhcV7iLdTH3BPp5X78vXZPP2sl4-bRInc2mSXFcotDOYamOAdOaUTtFLpUqvvR4vusiqotSlQSRSSpdAucsFCpClA7Vg96fcLrRfA8XebtshNONLKyWILAeVjSJxErnQxhiosl2o9xh-rAB7ZGdP7OzIzh7ZWTN67qbgodyT_3dMsNQvsf5o_w</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>Roth, Arnaud D</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>2002</creationdate><title>European experience of docetaxel and cisplatin in advanced gastric cancer</title><author>Roth, Arnaud D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2825-84fa14c5a64550e47c346ad233bd4d40e4497f9b4b5aaee334b0e8c81a102bc03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cisplatin - administration &amp; dosage</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fluorouracil - administration &amp; dosage</topic><topic>Gastric cancer</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Paclitaxel - administration &amp; dosage</topic><topic>Paclitaxel - analogs &amp; derivatives</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - pathology</topic><topic>Taxoids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roth, Arnaud D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roth, Arnaud D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>European experience of docetaxel and cisplatin in advanced gastric cancer</atitle><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle><addtitle>Gastric Cancer</addtitle><date>2002</date><risdate>2002</risdate><volume>5 Suppl 1</volume><issue>S1</issue><spage>27</spage><epage>29</epage><pages>27-29</pages><issn>1436-3291</issn><eissn>1436-3305</eissn><abstract>The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response rate of 56%) with a manageable safety profile. Up to 300 mg/m2 5-fluorouracil (5-FU) given by continuous infusion for 2 of 3 weeks can be added to this regimen without an increase in appreciable toxicity. The efficacy of docetaxel-based regimens remains to be established by a randomized phase III study. However, the results of such trials are eagerly awaited, as are data from studies of docetaxel-based combinations in the adjuvant and neoadjuvant settings.</abstract><cop>Japan</cop><pub>Springer Nature B.V</pub><pmid>12772884</pmid><doi>10.1007/s10120-002-0204-5</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1436-3291
ispartof Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2002, Vol.5 Suppl 1 (S1), p.27-29
issn 1436-3291
1436-3305
language eng
recordid cdi_proquest_journals_220178037
source Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List
subjects Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - administration & dosage
Disease Progression
Disease-Free Survival
Female
Fluorouracil - administration & dosage
Gastric cancer
Humans
Male
Middle Aged
Oncology
Paclitaxel - administration & dosage
Paclitaxel - analogs & derivatives
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Taxoids
title European experience of docetaxel and cisplatin in advanced gastric cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T06%3A33%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=European%20experience%20of%20docetaxel%20and%20cisplatin%20in%20advanced%20gastric%20cancer&rft.jtitle=Gastric%20cancer%20:%20official%20journal%20of%20the%20International%20Gastric%20Cancer%20Association%20and%20the%20Japanese%20Gastric%20Cancer%20Association&rft.au=Roth,%20Arnaud%20D&rft.date=2002&rft.volume=5%20Suppl%201&rft.issue=S1&rft.spage=27&rft.epage=29&rft.pages=27-29&rft.issn=1436-3291&rft.eissn=1436-3305&rft_id=info:doi/10.1007/s10120-002-0204-5&rft_dat=%3Cproquest_cross%3E944522761%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2825-84fa14c5a64550e47c346ad233bd4d40e4497f9b4b5aaee334b0e8c81a102bc03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=220178037&rft_id=info:pmid/12772884&rfr_iscdi=true